Head-to-head · WeighScore
Ageless vs Gala Health
The verdict
Gala Health takes it — 86/100 to 83/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier.
Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ageless | Gala Health |
|---|---|---|
| WeighScore | 83/100 | 86/100 |
| Grade | B | B |
| Scorecard rank | #24 | #8 |
| Semaglutide | $119/mo | Not disclosed |
| Tirzepatide | $169/mo | $179/mo |
| Coverage | Varies by state | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #24 · B
Strengths
- Unusually broad compounded menu — GLP-1, NAD+, sermorelin, TRT, LDN and more, in both injectable and oral formats
- Low headline GLP-1 pricing — semaglutide $119/mo, tirzepatide $169/mo — no insurance, with Klarna/Affirm financing
- Fully online: licensed-clinician review and discreet delivery, with upfront compounded/not-FDA disclosures
- Oral routes available (drops and troches), not injection-only
Where it loses points
- Everything is compounded and not FDA-approved — not equivalent to brand Wegovy/Ozempic/Zepbound
- Oral GLP-1 drops and troches lack robust absorption/efficacy evidence versus injectables
- No published state-availability list and no named legal entity or medical group
- Thin public track record, and advertised prices are floors set after clinical review
Graded #8 · B
Strengths
- Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
- Available in all 50 states
- Keeps a brand-name path open (Ozempic listed at $1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet
- Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 34 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.